Table 4.
Multivariable logistic regression models for 30- and 90-day postoperative mortality and Poisson regression model for duration of postoperative stay in patients diagnosed from 2012 to 2020 who had curative surgery for oesophagogastric cancer
| 30-day mortality | 90-day mortality | Duration of stay | ||||
|---|---|---|---|---|---|---|
| aOR (95% c.i.) (n = 17 650) | P value | aOR (95% c.i.) (n = 17 650) | P value | aIRR (95% c.i.) (n = 16 392) | P value | |
| Audit year | 0.93 (0.88–0.98) | 0.004 | 0.94 (0.91–0.98) | 0.003 | 0.98 (0.97–0.98) | <0.001 |
| Age (years) | 1.04 (1.02–1.05) | <0.001 | 1.03 (1.02–1.04) | <0.001 | 1.00 (1.00–1.01) | <0.001 |
| Male sex | 1.15 (0.87–1.53) | 0.318 | 1.15 (0.94–1.42) | 0.184 | 0.98 (0.95–1.00) | 0.103 |
| Deprivation quintiles | ||||||
| ȃ1 (least deprived) | 1 | 0.662 | 1 | 0.300 | 1 | <0.001 |
| ȃ2 | 1.09 (0.76–1.55) | 1.24 (0.95–1.61) | 1.02 (0.98–1.06) | |||
| ȃ3 | 1.10 (0.77–1.58) | 1.25 (0.96–1.64) | 1.03 (0.99–1.07) | |||
| ȃ4 | 1.29 (0.91–1.83) | 1.30 (0.99–1.70) | 1.02 (0.98–1.06) | |||
| ȃ5 (most deprived) | 1.22 (0.84–1.76) | 1.31 (0.99–1.73) | 1.09 (1.05–1.13) | |||
| Comorbidities | ||||||
| ȃNone | 1 | <0.001 | 1 | <0.001 | 1 | 0.001 |
| ȃ1 | 1.80 (1.37–2.37) | 1.56 (1.28–1.92) | 1.04 (1.01–1.07) | |||
| ȃ2 | 2.09 (1.51–2.88) | 1.84 (1.45–2.33) | 1.05 (1.01–1.09) | |||
| ȃ3 or more | 2.78 (1.89–4.08) | 2.58 (1.94–3.42) | 1.10 (1.04–1.16) | |||
| Tumour group | ||||||
| ȃOesophageal SCC | 1 | 0.146 | 1 | 0.195 | 1 | 0.007 |
| ȃOes ACA upper/mid | 1.02 (0.58–1.82) | 1.06 (0.69–1.64) | 0.93 (0.87–0.99) | |||
| ȃOes ACA lower (SI, SII) | 0.84 (0.56–1.27) | 0.84 (0.62–1.15) | 0.90 (0.86–0.94) | |||
| ȃStomach (w SIII) | 0.52 (0.28–0.96) | 0.64 (0.40–1.04) | 0.85 (0.79–0.90) | |||
| Clinical T category | ||||||
| ȃ0/1 | 1 | 0.350 | 1 | 0.152 | 1 | 0.008 |
| ȃ2 | 0.68 (0.43–1.06) | 1.07 (0.74–1.54) | 1.03 (0.98–1.08) | |||
| ȃ3 | 0.90 (0.59–1.37) | 1.37 (0.96–1.94) | 1.00 (0.95–1.05) | |||
| ȃ4 | 0.81 (0.44–1.47) | 1.19 (0.76–1.89) | 1.07 (1.00–1.14) | |||
| ȃX | 0.99 (0.53–1.87) | 1.44 (0.89–2.31) | 0.95 (0.89–1.02) | |||
| Clinical N category | ||||||
| ȃ0 | 1 | 0.517 | 1 | 0.162 | 1 | 0.124 |
| ȃ1 | 1.22 (0.92–1.62) | 1.27 (1.04–1.56) | 1.00 (0.97–1.03) | |||
| ȃ2 | 1.18 (0.80–1.74) | 1.28 (0.97–1.69) | 1.02 (0.98–1.07) | |||
| ȃ3 | 0.87 (0.37–2.05) | 0.97 (0.55–1.73) | 1.07 (0.99–1.15) | |||
| ȃX | 1.59 (0.72–3.50) | 1.32 (0.72–2.42) | 1.09 (0.99–1.19) | |||
| Performance status | ||||||
| ȃ0 | 1 | 0.041 | 1 | <0.001 | 1 | <0.001 |
| ȃ1 | 1.05 (0.82–1.35) | 1.05 (0.88–1.26) | 1.06 (1.03–1.09) | |||
| ȃ≥2 | 1.57 (1.09–2.25) | 1.74 (1.33–2.26) | 1.16 (1.11–1.22) | |||
| ȃNeoadjuvant therapy | 0.78 (0.60–1.02) | 0.068 | 0.73 (0.60–0.89) | 0.002 | 0.96 (0.93–0.99) | 0.008 |
| Main procedure | ||||||
| ȃOesophagectomy | 1 | 0.790 | 1 | 0.425 | 1 | <0.001 |
| ȃGastrectomy | 0.94 (0.57–1.53) | 0.85 (0.58–1.26) | 0.78 (0.74–0.82) | |||
| Trust volume | 0.99 (0.99–0.99) | <0.001 | 0.99 (0.99–0.99) | <0.001 | 0.99 (0.99–0.99) | <0.001 |
aOR, adjusted odds ratio; aIRR, adjusted incidence rate ratio; SCC, squamous cell carcinoma; Oes ACA, oesophageal adenocarcinoma; w SI–III, with Siewert type I–III. Bold values indicate statistically significant at p < 0.05.